What are the recommended dosing schedules for hepatitis B vaccination and the first‑line oral antivirals for chronic hepatitis B infection?

Hepatitis B Vaccination Dosing

For adults aged 19-59 years, the standard hepatitis B vaccination consists of three intramuscular doses administered at 0,1, and 6 months using either Engerix-B (20 μg) or Recombivax HB (10 μg), with alternative accelerated schedules available when rapid protection is needed. 1

Standard Vaccination Schedules by Age Group

Infants and Children

Birth Dose (Critical for Prevention)

• All infants should receive the first dose within 12 hours of birth, regardless of maternal hepatitis B surface antigen (HBsAg) status 1
• For infants born to HBsAg-positive mothers: administer both hepatitis B vaccine AND hepatitis B immune globulin (HBIG) within 12 hours at separate anatomical sites 1
• Only single-antigen vaccine can be used for the birth dose—combination vaccines like Pediarix cannot be given before 6 weeks of age 1

Standard Infant Schedule:

• ≥2,000 g birthweight, HBsAg-negative mother: Birth, 1-2 months, 6 months (3 doses total) 1
• <2,000 g birthweight: Birth dose does NOT count toward the series; give 3 additional doses starting at 1 month (4 doses total) 1
• The final dose must not be administered before 24 weeks (164 days) of age 1

Adolescents (11-19 years)

Standard 3-dose schedule: 0,1, and 6 months 2

Alternative 2-dose schedule (ages 11-15 only): Recombivax HB adult formulation (10 μg) at 0 and 4-6 months 1, 3

Adults (≥18 years)

Standard schedules (choose one):

• 0,1,6 months (most common) 1
• 0,1,4 months (acceptable alternative) 1
• 0,2,4 months (acceptable alternative) 1

Newer vaccine options with different schedules:

• Heplisav-B: 2 doses at 0 and 1 month (20 μg each) - achieves ~90% seroprotection versus 70.5-90.2% with Engerix-B 2, 3
• PreHevbrio: 3 doses at 0,1,6 months (10 μg each) 3
• Twinrix (combined hepatitis A/B): Standard 0,1,6 months OR accelerated 0,7,21-30 days, then 12 months 1, 3

Important note: Heplisav-B and PreHevbrio should NOT be used in pregnant women or hemodialysis patients due to insufficient safety data 3. Use Engerix-B, Recombivax HB, or Twinrix instead.

Special Populations

Hemodialysis Patients

Higher doses required due to poor immune response:

• Recombivax HB: 40 μg at 0,1,6 months 1
• Engerix-B: 40 μg at 0,1,2,6 months (4-dose schedule) 1, 3
• Annual anti-HBs testing recommended; give booster when levels fall below 10 mIU/mL 1

Pregnant Women with High Viral Load

• Women with HBV DNA >200,000 IU/mL should receive tenofovir disoproxil fumarate (TDF) starting at 28-32 weeks gestation to prevent perinatal transmission 1
• This is in addition to immediate neonatal vaccination and HBIG 1

Immunocompromised Persons

• Consider annual anti-HBs testing and booster doses for those with ongoing exposure risk 1
• Higher doses may be necessary, though data are limited 4

Critical Timing Rules

Minimum intervals that must be respected:

• Between doses 1 and 2: 4 weeks minimum 1
• Between doses 2 and 3: 8 weeks minimum 1
• Between doses 1 and 3: 16 weeks minimum 1
• Doses given ≤4 days before minimum interval are considered valid 1

If schedule is interrupted:

• Do NOT restart the series 1
• Give the next dose as soon as possible
• Maintain minimum intervals between remaining doses 1

---

First-Line Oral Antivirals for Chronic Hepatitis B

For treatment-naïve adults with chronic hepatitis B requiring antiviral therapy, use entecavir 0.5 mg daily, tenofovir disoproxil fumarate (TDF) 300 mg daily, or tenofovir alafenamide (TAF) 25 mg daily as first-line monotherapy. 5

Dosing by Medication

Entecavir

• Standard dose: 0.5 mg once daily on an empty stomach 5
• Higher dose (1 mg daily) required if:
  • Lamivudine-experienced patient 5
  • Decompensated cirrhosis 5
• Pediatric dosing: Weight-based (consult package insert) 5

Tenofovir Disoproxil Fumarate (TDF)

• Standard dose: 300 mg once daily 5
• Preferred in pregnancy: Use in third trimester for women with HBV DNA >200,000 IU/mL 6
• Caution: Monitor renal function and bone density; avoid in patients with pre-existing renal insufficiency or osteoporosis 6

Tenofovir Alafenamide (TAF)

• Standard dose: 25 mg once daily 5
• Preferred over TDF when:
  • Concomitant renal insufficiency present 6
  • Osteoporosis present 6
• Better renal and bone safety profile compared to TDF 7

Treatment Indications (Who Needs Antivirals)

Treat if ANY of the following:

• Liver cirrhosis with detectable HBV DNA (any level) 6
• HBV DNA >2,000 IU/mL PLUS elevated ALT/AST 6
• HBV DNA >2,000 IU/mL PLUS evidence of fibrosis 6
• HBV DNA >2,000 IU/mL PLUS risk factors for hepatocellular carcinoma 6

Do NOT treat "immune-tolerant" phase:

• HBV DNA >1 million IU/mL but normal ALT and no fibrosis 5
• These patients require monitoring, not immediate treatment

Expected Treatment Outcomes

HBeAg-Positive Disease (after 1 year of therapy)

• HBV DNA suppression: 76% (entecavir), 73% (TDF), 73% (TAF) 5
• HBeAg seroconversion: 21-22% (entecavir/TDF), 18% (TAF) 5
• ALT normalization: 68-81% 5
• HBsAg loss (functional cure): 1-4% at 2 years, increases to 8-11% at 3 years 5

HBeAg-Negative Disease (after 1 year of therapy)

• HBV DNA suppression: 90-93% (all three agents) 5
• ALT normalization: 76-88% 5
• HBsAg loss: 0-10% 5

Common Pitfalls to Avoid

1. Do NOT use entecavir in lamivudine-experienced patients at standard dose—resistance risk is high; use 1 mg daily instead 5

2. Do NOT use Heplisav-B or PreHevbrio in pregnant women—insufficient safety data; use Engerix-B or Recombivax HB 3

3. Do NOT count the birth dose in infants <2,000 g toward the vaccine series—they need 4 total doses 1

4. Do NOT give combination vaccines (Pediarix) before 6 weeks of age—only single-antigen vaccine for birth dose 1

5. Do NOT use TDF in patients with renal disease or osteoporosis—switch to TAF or entecavir 6

6. Do NOT forget HBIG for infants born to HBsAg-positive mothers—vaccine alone is insufficient 1

7. Do NOT restart interrupted vaccine series—just continue with appropriate intervals 1